US EditionHoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
- Hoth Therapeutics announced on March 31, 2025, the receipt of a USPTO Filing Receipt in New York.
- Hoth seeks to expand its intellectual property for HT-001, its lead clinical asset.
- The patent application is formulation-specific, protecting HT-001's unique composition and delivery method.
- Robb Knie, Hoth Therapeutics CEO, stated the receipt marks a critical milestone for HT-001 development.
- The USPTO Filing Receipt confirms formal acceptance, allowing the patent application to proceed for examination.
Insights by Ground AI
Does this summary seem wrong?
21 Articles
21 Articles
All
Left
Center
6
Right
3
The Berkshire Eagle+20 Reposted by 20 other sources
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
NEW YORK, March 31, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing Receipt from the United States Patent and Trademark Office (USPTO) for a new patent…
Coverage Details
Total News Sources21
Leaning Left0Leaning Right3Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
